The role of interleukin-13 in the management of atopic dermatitis: An expert consensus panel

Atopic dermatitis is a chronic inflammatory skin condition driven by immune dysregulation, with interleukin-13 playing a central role in its pathogenesis. Recent advances in targeted biologic therapies have shown promising results in treating moderate-to-severe atopic dermatitis. A comprehensive literature review of PubMed and Google Scholar was conducted to identify studies related to interleukin-13 inhibition in atopic dermatitis. An expert panel reviewed and graded the evidence using Strength of Recommendation Taxonomy criteria and utilized a modified Delphi process to formulate consensus statements on the role of interleukin-13 inhibitors. Based on selected literature, the panel developed 14 consensus statements, all receiving unanimous approval. Key findings include the rapid efficacy, sustained benefits, and favorable safety profiles of interleukin-13 inhibitors. Differences between available interleukin-13 inhibitors included pain of injection, speed of onset, durability of efficacy, and number of injections needed to maintain efficacy. Interleukin-13 plays a pivotal role in atopic dermatitis pathogenesis, driving inflammation, pruritus, and barrier dysfunction. Targeted therapies, including interleukin-13 inhibitors, provide rapid, durable, and safe options for managing moderate-to-severe atopic dermatitis. This consensus highlights interleukin-13 inhibition as a cornerstone in advancing atopic dermatitis treatment strategies, offering improved patient outcomes and quality of life.

Authors

Institutions

Publication Details

Journal
Dermatology Online Journal
Published
2025-09-08
DOI
https://doi.org/10.25251/tvshr813
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The role of interleukin-13 in the management of atopic dermatitis: An expert consensus panel

Mark Lebwohl, Natasha Atanaskova-Mesinkovska, Michael D. Cameron, Tejesh Patel et al.
Dermatology Online Journal
Dermatology and Skin Diseases
article

The role of interleukin-13 in the management of atopic dermatitis: An expert consensus panel

Mark Lebwohl, Natasha Atanaskova-Mesinkovska, Michael D. Cameron, Tejesh Patel, Joshua Burshtein, Theodore J. Daly, Dawn A. Merritt, Lawrence F. Eichenfield, Danny Zakria, Darrell S. Rigel, Brooke Bartley, Milaan Shah, Angela Rosenberg, Lisa Swanson, Lauren DeBusk
article en

Abstract

Atopic dermatitis is a chronic inflammatory skin condition driven by immune dysregulation, with interleukin-13 playing a central role in its pathogenesis. Recent advances in targeted biologic therapies have shown promising results in treating moderate-to-severe atopic dermatitis. A comprehensive literature review of PubMed and Google Scholar was conducted to identify studies related to interleukin-13 inhibition in atopic dermatitis. An expert panel reviewed and graded the evidence using Strength of Recommendation Taxonomy criteria and utilized a modified Delphi process to formulate consensus statements on the role of interleukin-13 inhibitors. Based on selected literature, the panel developed 14 consensus statements, all receiving unanimous approval. Key findings include the rapid efficacy, sustained benefits, and favorable safety profiles of interleukin-13 inhibitors. Differences between available interleukin-13 inhibitors included pain of injection, speed of onset, durability of efficacy, and number of injections needed to maintain efficacy. Interleukin-13 plays a pivotal role in atopic dermatitis pathogenesis, driving inflammation, pruritus, and barrier dysfunction. Targeted therapies, including interleukin-13 inhibitors, provide rapid, durable, and safe options for managing moderate-to-severe atopic dermatitis. This consensus highlights interleukin-13 inhibition as a cornerstone in advancing atopic dermatitis treatment strategies, offering improved patient outcomes and quality of life.

Dermatology Online JournalVol. 31(4)
Cameron University (US), Mount Sinai Health System (US), Medical University of South Carolina (US), University of Tennessee Health Science Center (US), University of California, Irvine (US), Garden City Community College (US), University of California San Diego (US), University of Illinois Chicago (US), University of Chicago (US), Southwestern Medical Center (US), Northwest Clinical Trials (US), Elks Rehabilitation Hospital (US), OAK Orthopedics (US), Southwestern Medical Center (US), New York University (US), The University of Texas Southwestern Medical Center (US), Icahn School of Medicine at Mount Sinai (US)
Amgen, Bristol-Myers Squibb, National Alopecia Areata Foundation, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, AbbVie, Regeneron Pharmaceuticals, Incyte, Celltrion, Castle Biosciences, Meiji Seika Pharma, Galderma, Sun Pharma, Bausch Health, LEO Pharma, Genentech, UCB Pharma
Openalex Percentile: Top 47%
Dermatology and Skin Diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.